Radiation Therapy During Surgery in Treating Older Women With Stage I Breast Cancer

This study has been completed.
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
First received: November 9, 2007
Last updated: May 12, 2011
Last verified: December 2007

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving intraoperative radiation therapy may reduce the amount of normal tissue that needs to be removed.

PURPOSE: This phase II trial is studying how well giving radiation therapy during surgery works in treating older women with stage I breast cancer.

Condition Intervention Phase
Breast Cancer
Procedure: axillary lymph node dissection
Procedure: conventional surgery
Procedure: sentinel lymph node biopsy
Radiation: intraoperative radiation therapy
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 2 Study Evaluating the Feasibility and the Reproducibility of Concentrated Radiotherapy and Focalized Electrontherapy During Surgery for the Treatment of Older Patients With Breast Cancer

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Feasibility [ Designated as safety issue: No ]
  • Reproducibility [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Quality of life (QLQ-C30) [ Designated as safety issue: No ]
  • Satisfaction with care [ Designated as safety issue: No ]
  • Tolerability [ Designated as safety issue: Yes ]
  • Cosmetic results [ Designated as safety issue: No ]
  • Economic impact [ Designated as safety issue: No ]
  • Relapse-free survival [ Designated as safety issue: No ]
  • Disease-specific survival [ Designated as safety issue: No ]

Estimated Enrollment: 42
Study Start Date: January 2004
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Detailed Description:



  • Study the feasibility and reproducibility of intraoperative radiotherapy as the only treatment after lumpectomy in older women with stage I breast cancer.


  • Study the impact of this regimen on maintaining self-care.
  • Study the quality of life (QLQ-C30) and satisfaction with care.
  • Study regimen tolerance and cosmetic results.
  • Evaluate the economic impact of this treatment.
  • Study relapse-free and disease-specific survival.

OUTLINE: Patients undergo conservative breast surgery and axillary node dissection (sentinel node or classic resection). At this point, patients must have either negative axillary lymph nodes after removal of ≥ 6 lymph nodes, negative sentinel nodes, or have had a limited lumpectomy with negative margins ≥ 2 mm. Patients undergo intraoperative radiotherapy during surgery, before closing and reconstruction of the breast.

Patients may begin hormonal therapy after completing study therapy.

After completion of study therapy, patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years.


Ages Eligible for Study:   65 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No


Inclusion criteria:

  • Histologically confirmed stage I breast cancer

    • Size ≤ 20 mm (by ultrasound), N0, any quadrant
  • Hormone receptor status not specified

Exclusion criteria:

  • Distant metastases
  • Inflammatory breast cancer
  • Lobular in situ disease
  • Invasive cancer or ductal carcinoma in situ
  • Nonepithelial disease or sarcoma
  • Multicentric disease
  • Lymphatic embolism
  • Margins of safety unknown or positive (in situ or invasive)
  • Preoperative mammography showing diffuse microcalcification


  • Female
  • Menopausal
  • Karnofsky 70-100%
  • No other prior cancer except basal cell skin cancer, uterine epithelioma in situ, or other cancer in complete remission for the past 5 years
  • No geographic, social, or psychiatric reasons that would impede participation in study treatment


  • See Disease Characteristics
  • No prior neoadjuvant therapy
  • No concurrent participation in another study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00556777

Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
Montpellier, France, 34298
Sponsors and Collaborators
Institut du Cancer de Montpellier - Val d'Aurelle
Study Chair: Jean-Bernard Dubois, MD Institut du Cancer de Montpellier - Val d'Aurelle
  More Information

ClinicalTrials.gov Identifier: NCT00556777     History of Changes
Other Study ID Numbers: CDR0000574074  CLCC-IORT-Sein  INCA-RECF0284 
Study First Received: November 9, 2007
Last Updated: May 12, 2011
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage I breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms by Site
Skin Diseases

ClinicalTrials.gov processed this record on May 26, 2016